SCHEMBL17216784

SCHEMBL17216784

N#Cc1ccc([C]=NOCc2ccc(Cl)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.47
▸ MAOA P21397 2/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ GAA P10253 1/20 0.47
▸ L3MBTL1 Q9Y468 3/20 0.44
▸ CYP19A1 P11511 1/20 0.42
▸ CCR5 P51681 1/20 0.41
▸ LOXL2 Q9Y4K0 2/20 0.41
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ AGXT P21549 1/20 0.39
▸ CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17218655 1.00 MAOB (0.47) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17218653 1.00 MAOB (0.47) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17216782 1.00 MAOB (0.47) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17218441 0.92 NPC1 (0.53) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17219095 0.92 IDO1 (0.45) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17218438 0.92 NPC1 (0.53) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17219096 0.92 IDO1 (0.45) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17218403 0.85 NPC1 (0.59) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17218400 0.85 NPC1 (0.59) MAOBMAOASMN1; SMN2NPC1RAB9A
SCHEMBL17217581 0.85 MRGPRX4 (0.46) MAOBMAOASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 MAOB 3611/4885MAOA 3360/4885SMN1; SMN2 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback